Aquestive Therapeutics, Inc.
Calidad de datos: 100%
AQST
Nasdaq
Manufacturing
Chemicals
$4.08
▼
$0.09
(-2.16%)
Cap. Mercado: 508.32 M
Precio
$4.17
Cap. Mercado
508.32 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—
Quick Summary
Puntos Clave
Revenue declined -3.25% annually over 5 years
Negative free cash flow of -52.99 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 19.36%
Capital efficient — spends only 1.26% of revenue on capex
Crecimiento
Revenue Growth (5Y)
-3.25%
Below sector avg (1.82%)
Revenue (1Y)-22.61%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Calidad
Return on Equity
N/A
ROIC-53.83%
Net Margin-188.09%
Op. Margin-159.50%
Seguridad
Debt / Equity
N/A
Current Ratio5.93
Interest Coverage-6.39
Valoración
PE (TTM)
-6.07
Below sector avg (-1.47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Historial de Precios
Tendencias Financieras
Comparación con Pares
vs mediana del sector Manufacturing (1364 pares)
Comparación con Pares
vs mediana del sector Manufacturing (1364 pares)| Métrica | Acción | Mediana del Sector |
|---|---|---|
| P/E | -6.1 | -1.5 |
| P/B | — | 1.6 |
| ROE % | — | -53.3 |
| Net Margin % | -188.1 | -41.5 |
| Rev Growth 5Y % | -3.3 | 1.8 |
| D/E | — | 0.3 |
Precio Objetivo de Analistas
9 analistas
Buy
Actual
$4.08
Objetivo
$8.89
$6.00
$9.00
$11.00
Pronóstico
P/E Futuro
-7.03
EPS Futuro
-$0.58
Ingresos Est.
71.85 M
Estimaciones de Ganancias
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| FY2027 |
-$0.58
-$0.75 – -$0.41
|
71.85 M | 2 |
| FY2026 |
-$0.46
-$0.55 – -$0.37
|
48.07 M | 2 |
| Período | EPS Est. | Ingresos Est. | Analistas |
|---|---|---|---|
| 2026 Q2 |
-$0.12
-$0.14 – -$0.09
|
11.75 M | 2 |
| 2026 Q1 |
-$0.13
-$0.14 – -$0.12
|
10.90 M | 2 |
Sorpresas de Ganancias
Últimos 4 trimestres
| Trimestre | EPS Est. | EPS Real | Sorpresa |
|---|---|---|---|
| Q42025 | -$0.12 | -$0.14 | -18.1% |
| Q32025 | -$0.11 | -$0.11 | -4.2% |
| Q22025 | -$0.17 | -$0.12 | +32.3% |
| Q12025 | -$0.16 | -$0.22 | -39.7% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -22.61% | Revenue Growth (3Y) | -6.16% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -3.25% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 44.55 M | Net Income (TTM) | -83.78 M |
| ROE | N/A | ROA | -65.14% |
| Gross Margin | N/A | Operating Margin | -159.50% |
| Net Margin | -188.09% | Free Cash Flow (TTM) | -52.99 M |
| ROIC | -53.83% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 5.93 |
| Interest Coverage | -6.39 | Asset Turnover | 0.35 |
| Working Capital | 126.10 M | Tangible Book Value | -4.11 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -6.07 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | 11.41 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -10.43% | ||
| Market Cap | 508.32 M | Enterprise Value | 424.25 M |
| Per Share | |||
| EPS (Diluted TTM) | -0.78 | Revenue / Share | 0.37 |
| FCF / Share | -0.43 | OCF / Share | -0.43 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 1.26% | FCF Conversion | 63.25% |
| SBC-Adj. FCF | -60.82 M | Growth Momentum | -19.36 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 44.55 M | 57.56 M | 50.58 M | 47.68 M | 50.83 M |
| Net Income | -83.78 M | -44.14 M | -7.87 M | -54.41 M | -70.54 M |
| EPS (Diluted) | -0.78 | -0.51 | -0.13 | -1.12 | -1.85 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -71.05 M | -30.77 M | -15.10 M | -42.07 M | -34.68 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 17.19 M | 20.28 M | 13.10 M | 17.48 M | 17.05 M |
| SG&A Expenses | 79.85 M | 50.18 M | 31.75 M | 52.88 M | 53.48 M |
| D&A | 548,000.0 | 718,000.0 | 1.35 M | 2.39 M | 2.96 M |
| Interest Expense | 11.12 M | 11.12 M | 6.34 M | 6.55 M | 10.05 M |
| Income Tax | 0.0 | -14,000.0 | 245,000.0 | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 160.43 M | 101.42 M | 57.42 M | 57.07 M | 61.99 M |
| Total Liabilities | 194.09 M | 161.58 M | 163.91 M | 175.62 M | 144.13 M |
| Shareholders' Equity | -33.66 M | -60.16 M | -106.49 M | -118.55 M | -82.13 M |
| Total Debt | 45.00 M | 45.00 M | 45.00 M | — | — |
| Cash & Equivalents | — | — | — | — | — |
| Current Assets | 149.27 M | 88.22 M | 40.97 M | 39.89 M | 47.26 M |
| Current Liabilities | 47.61 M | 18.87 M | 18.31 M | 39.53 M | 21.96 M |
{"event":"ticker_viewed","properties":{"ticker":"AQST","listing_kind":"stock","pathname":"/stocks/aqst","exchange":"Nasdaq","country":"US"}}

